Title
Efficacy and Safety of Rezum System Water Vapor Treatment for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
Publication Date
2015
Journal Title
Urology
Abstract
OBJECTIVES: To assess 1 year efficacy and safety data from pilot trials of the Rezum System water vapor to treat lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). METHODS: A total of 65 men with symptoms of moderate to severe BPH were enrolled in pilot studies at centers in the Dominican Republic, the Czech Republic, and Sweden. Each patient was treated with transurethral delivery of sterile water vapor (steam). International Prostate Symptom Score (IPSS), peak urinary flow (Qmax), quality of life (QoL), post void residual (PVR), International Index of Erectile Function (IIEF) and prostate-specific antigen (PSA) were evaluated at 1 week and 1, 3, 6 and 12 months post-treatment. Safety was also assessed. RESULTS: Statistically significant clinical improvements at 1, 3, 6, and 12 months were reported for IPSS (decreased by 6.8, 13.4 13.1, and 12.5 points, respectively) and Qmax (increased by 2.0, 4.7, 4.3, and 4.6 ml/sec, respectively). At 12 months, these results equated to a 56% improvement in IPSS (P
Volume Number
86
Issue Number
5
Pages
1042-7
Document Type
Article
EPub Date
2015/07/29
Status
Northwell Researcher
Facility
Northwell Health
Primary Department
Urology
PMID
DOI
10.1016/j.urology.2015.05.046